Tech Company Financing Transactions
Aulos Bioscience Funding Round
On 8/1/2023, Aulos Bioscience announced $20 million in Series A funding from Apple Tree Partners.
Transaction Overview
Company Name
Announced On
8/1/2023
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Apple Tree Partners (Lead Investor) (Michael Ehlers)
Proceeds Purpose
The company intends to use the funds to advance its lead human monoclonal antibody candidate, AU-007, through its initial Phase 2 clinical study in solid tumor cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 Main St. 12th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL-2 targeting antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yanay Ofran
Chief Operating Officer
Micah Pearlman
Vice President
Timothy Wyant
Browse more venture capital transactions:
Prev: 8/1/2023: Epiterna venture capital transaction
Next: 8/1/2023: GoTab venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs